135271-49-7 Usage
Description
(R)-Salmeterol 1-hydroxy-2-naphthoic acid salt is a chemical salt form of (R)-salmeterol, a long-acting beta2-adrenergic agonist. It is created by combining (R)-salmeterol with 1-hydroxy-2-naphthoic acid, resulting in a more stable, water-soluble form of the drug. (R)-Salmeterol 1-hydroxy-2-naphthoic acid salt works by relaxing the smooth muscles in the airways, which allows for easier breathing and reduces symptoms of asthma and chronic obstructive pulmonary disease (COPD).
Uses
Used in Pharmaceutical Industry:
(R)-Salmeterol 1-hydroxy-2-naphthoic acid salt is used as a therapeutic agent for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It functions by relaxing the smooth muscles in the airways, facilitating easier breathing and alleviating the symptoms associated with these respiratory conditions.
Additionally, the 1-hydroxy-2-naphthoic acid salt form of (R)-salmeterol may offer improved pharmacokinetic properties and stability compared to the free base form, potentially making it a more effective and convenient treatment option for patients with respiratory conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 135271-49-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,5,2,7 and 1 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 135271-49:
(8*1)+(7*3)+(6*5)+(5*2)+(4*7)+(3*1)+(2*4)+(1*9)=117
117 % 10 = 7
So 135271-49-7 is a valid CAS Registry Number.
135271-49-7Relevant articles and documents
Control of the physical form of salmeterol xinafoate
Beach, Steve,Latham, David,Sidgwick, Colin,Hanna, Mazen,York, Peter
, p. 370 - 376 (1999)
Two approaches to the generation of particles of the phenethanolamine, salmeterol xinafoate, are discussed. To produce particles with good flow properties a fast cooling crystallisation process was developed which delivered salmeterol xinafoate as spherical agglomerates of microcrystals which had good powder flow characteristics and could be micronised efficiently in a fluid energy mill. In a radically different approach, salmeterol xinafoate was crystallised using supercritical carbon dioxide in the SEDS (solution enhanced dispersion by supercritical fluids) process. By means of this technique the solid state form, crystal habit, and particle size of salmeterol xinafoate could be effectively controlled.
PROCESS FOR THE PREPARATION OF SALMETEROL XINAFOATE
-
Page/Page column 15; 16, (2017/11/03)
The present invention relates to an improved process for the preparation of Salmeterol Xinafoate of Formula (I).
SUBSTITUTED ETHANOLAMINES
-
Page/Page column 22-23, (2010/02/17)
The present invention relates to new substituted ethanolamine adrenergic receptor modulators, pharmaceutical compositions thereof, and methods of use thereof.